Reports Q2 revenue $20.5M vs. $23.1M last year. “We made solid progress in the second quarter exceeding our revenue guidance. In my short time as CEO, I have already seen first-hand the dedication of our team. The fundamentals of the business remain intact with attractive margins and promising technologies serving high-growth markets,” said John Duke, President and CEO. “Our priorities are to grow our core business and re-structure our balance sheet. We are taking immediate actions on both fronts and expect these actions to position us well for revenue growth and margin expansion in 2026 and beyond.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- HBIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Harvard Bioscience: Strong Q2 Performance and Strategic Leadership Changes Drive Buy Rating
- Harvard Bioscience Announces CEO Succession Plan
- Harvard Bioscience announces CEO succession plan, appointment of two directors
- Harvard Bioscience Faces Nasdaq Compliance Challenge